Evanston-based biopharmaceutical company Aptinyx Inc. Thursday said a drug it is studying to treat patients with painful diabetic peripheral neuropathy failed a recent clinical study.The drug, NYX-2925, did not achieve statistically significant separation from a placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale, the company said.
Related posts
-
Elgin police report rise in serious crimes, gunfire incidents in 2024
Elgin police report a rise in serious crimes and gun violence in 2024 but say a... -
District 21 spending $1.5 million to convert old administration building into storage space
Wheeling Township Elementary District 21 will spend $1.5 million to renovate its former administration building into... -
Buffalo restaurant in Buffalo Grove closing after decades serving pancakes, burgers and more
The Buffalo Restaurant & Ice Cream Parlor in Buffalo Grove is closing for good.